2 Study Matches
A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
This research is being done to find out the safety of propranolol and, identify the maximum tolerated dose of propranolol that can be administered in combination with pembrolizumab in patients with unresectable stage III and stage IV melanoma. This study will evaluate this novel combination of pembrolizumab and propranolol to see what effect it may have on how your cancer responds to the treatment combination.
18 year(s) or older
Inclusion Criteria:Age >=18 years.
Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma.
Have measurable disease per RECIST v1.1
Have an ECOG performance status 0-1
Exclusion Criteria:Participants who have received previous immunotherapy for any cancer (excluding melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors.
Participants with chronic autoimmune diseases
Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer ≥ 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
18 year(s) or older
Inclusion Criteria:Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Exclusion Criteria:Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone